Thrombosis
Drug research and approvals for thrombosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 437 studies of thrombosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 19 drug trials for it since 2013, FDA has 3 approved and 5 open orphan designations naming it, and the EU has 3 authorised medicines for it.
- Recruiting worldwide: 437
- Trials authorized in Canada: 19
- FDA orphan approvals: 3
- EU medicines: 3
- Chemotherapy-Minimized Blank Microsphere Transarterial Embolization (BMS-TACE) Plus Low-Dose Lenvatinib, Iparomlimab…NCT07951021 · Phase 2 · Sun Yat-sen University · starts Oct 15, 2026
- Effect of Xylitol Chewing Gum Consumption on Coagulation Parameters and Salivary Oral Microbiological Markers in…NCT07951229 · Not applicable · Bezmialem Vakif University · starts Jul 1, 2026
- Evaluation of the Predictive Value of Microemboli Detected by Robotic Transcranial Doppler (TCD) for the Occurrence of…NCT07932080 · Not applicable · CHC Montlegia · starts Dec 1, 2026
- Early Detection and Kinetics of Sepsis-Induced Coagulopathy in Severe Burn PatientsNCT07914205 · Not reported · Center for Traumatology and Major Burns, Ben Arous · starts Aug 1, 2026
- Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple MyelomaNCT07907211 · Phase 4 · Chen Lijuan · starts Feb 1, 2024
- Clinical Management and Outcomes After Lung Scintigraphy for Suspected Pulmonary Embolism in the Emergency DepartmentNCT07905781 · Not reported · Antalya Health Sciences University · starts Oct 10, 2026
- Danang Cerebral Venous Thrombosis RegistryNCT07890675 · Not reported · Da Nang Hospital · starts Oct 9, 2025
- Comparison of DOACs and LMWH for Thromboprophylaxis After Total Knee ArthroplastyNCT07869615 · Not applicable · Military Hospital of Tunis · starts Sep 15, 2026
- TRiP-cast Score Validation and Evaluation of Adherence to Preventive Anticoagulant Treatment in Patients With Lower…NCT07863115 · Not reported · University of Monastir · starts Sep 1, 2025
Approved 24 of 52
- AspirinCyclooxygenase inhibitor
- ApixabanCoagulation factor X inhibitor
- RivaroxabanCoagulation factor X inhibitor
- WarfarinVitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor
- ClopidogrelPurinergic receptor P2Y12 antagonist
- Enoxaparin sodiumAntithrombin-III activator
- BivalirudinThrombin inhibitor
- AlteplaseTissue-type plasminogen activator exogenous protein
- HeparinAntithrombin-III activator
- TicagrelorPurinergic receptor P2Y12 negative allosteric modulator
- Dabigatran etexilateThrombin inhibitor
- EdoxabanCoagulation factor X inhibitor
- LepirudinThrombin inhibitor
- ArgatrobanThrombin inhibitor
- TenecteplaseTissue-type plasminogen activator exogenous protein
- VorapaxarProteinase-activated receptor 1 antagonist
- BetrixabanCoagulation factor X inhibitor
- CilostazolPhosphodiesterase 3A inhibitor
- Dalteparin sodiumAntithrombin-III activator
- FondaparinuxAntithrombin-III activator
- TiclopidinePurinergic receptor P2Y12 antagonist
- XimelagatranThrombin inhibitor
- DesirudinThrombin inhibitor
- StreptokinasePlasminogen activator
Phase 3 12 of 23
- BusulfanDNA inhibitor
- CytarabineDNA inhibitor
- EpirubicinDNA inhibitor
- Medroxyprogesterone acetateProgesterone receptor agonist
- ProgesteroneProgesterone receptor agonist
- Estrogens, conjugatedEstrogen receptor agonist
- Ethiodized oilDiagnostic agent
- CyclophosphamideDNA inhibitor
- AcetylcysteineGlutathione precursor
- AlfimepraseFibrinogen hydrolytic enzyme
- Idrabiotaparinux sodiumCoagulation factor X inhibitor
- Salicylic acid
Phase 2 12 of 16
- BMS-986141Proteinase activated receptor 4 antagonist
- CarboplatinDNA inhibitor
- FluorouracilThymidylate synthase inhibitor
- Vitamin k
- Endostatin, n-terminal-mggshhhhh
- Menaquinone 6
- Tioclomarol
- Beraprost
- Ditazole
- Cloricromen
- Clorindione
- Diphenadione
Phase 1 or earlier 11
- MilvexianCoagulation factor XI inhibitor
- ItraconazoleCytochrome P450 51 inhibitor
- SorafenibSerine/threonine-protein kinase RAF inhibitor
- DiltiazemVoltage-gated L-type calcium channel blocker
- RifampinBacterial DNA-directed RNA polymerase inhibitor
- ToripalimabProgrammed cell death protein 1 antagonist
- Egaptivon pegolvon Willebrand factor inhibitor
- Prothrombin complex concentrateCoagulation factor VII exogenous protein
- BMS-962212
- BMS-986120
- Gruticibart
How its trials ended
1,532 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 316 whose ending is known, 44% met their primary endpoint, 10% missed it and 46% stopped early.
- Completed, result not reported63842%
- Ongoing29920%
- Status unknown27918%
- Met its primary endpoint1399%
- Stopped: other or unclear775%
- Stopped: enrollment or feasibility362%
- Missed its primary endpoint322%
- Stopped: funding101%
- Stopped: lack of efficacy81%
- Stopped: sponsor or business decision81%
- Stopped: safety6<1%
| Sep 25, 2026 | Open-label, multi-center, single-dose phase 1 study to investigate the pharmacokinetics, safety, and tolerability of milvexian in pediatric patients from 28…Milvexian (BMS-986177, JNJ-70033093) | Johnson & Johnson | Pending |
| Jul 30, 2026 | A phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess efficacy and safety of REGN7508, a monoclonal antibody against fxi, for…REGN7508 | Regeneron | Pending |
| Aug 13, 2025 | Avoiding risks of thrombosis and bleeding in surgery (ARTS): an international randomized controlled trial evaluating apixaban versus no anticoagulation in…Apixaban | Dr. Kari Tikkinen | Ongoing |
| Feb 20, 2025 | A pilot randomized double-blinded comparison of full treatment dose rivaroxaban for 90 days to prophylactic dose rivaroxaban for 45 days in patients with lower…Rivaroxaban | Ottawa Hospital Research Institute | Ongoing |
| May 7, 2024 | The impact of additional post-operative doses of tranexamic acid on pain, mobility and bleeding following total hip and total knee arthroplasty: a randomized…Tranexamic acid | ST MARY's RESEARCH CENTRE | Ongoing |
| May 2, 2024 | A randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of bay 3018250 in patients with symptomatic proximal deep…Bay 3018250 | Bayer | Closed |
| May 2, 2024 | Colchicine to quench the inflammatory response after deep vein thrombosis: a randomized controlled pilot trial (the conquer-dvt pilot trial)Colchicine | Ottawa Hospital Research Institute | Ongoing |
| Dec 24, 2020 | A randomized controlled trial on the use of postoperative extended venous thromboprophylaxis in patients with inflammatory bowel disease. a pilot studyApixaban | McMaster University | Ongoing |
| Jun 25, 2020 | Factor xi lica to reduce thrombotic events in end-stage renal disease patients on hemodialysis: a phase 2, randomized, double-blind, placebo-controlled study…Bay 2976217 | Bayer | Closed |
| Jun 18, 2020 | Long-term treatment of cancer associated vte: reduced vs full dose of apixaban : api-cat study for apixaban cancer associated thrombosisApixaban | Assistance Publique - Hôpitaux De Paris | Closed |
| Mar 30, 2007 | CeprotinPrevention and treatment of venous thrombosis and purpura fulminans | Baxalta US, Inc. | Approved |
| Mar 14, 1997 | AgrylinTreatment of patients with essential thrombocythemia to reduce the elevated platelet count and the risk of thrombosis and to ameliorate… | Takeda Development Center Americas, Inc. | Approved |
| Dec 30, 1991 | Thrombate IIIFor replacement therapy in congenital deficiency of AT-III for prevention and treatment of thrombosis and pulmonary emboli. | Bayer Corporation | Approved |
| Apr 8, 2024 | TecarfarinPrevention of thromboembolism and thrombosis in patients with an implanted mechanical circulatory support device (left ventricular assist… | Cadrenal Therapeutics | Designated |
| Dec 30, 2020 | N-Benzothiazol-2-yl-4-(2-hydroxy-3-methoxy-benzylamino)-beze…Prophylaxis of thrombosis in patients with heparin-induced thrombocytopenia | Cadrenal Therapeutics, Inc. | Designated |
| Nov 2, 2005 | BivalirudinFor use as an anticoagulant in patients with or at risk of heparin-induced thrombocytopenia/heparin-induced thrombocytopenia thrombosis… | The Medicines Company | Designated |
| Jun 18, 2001 | Reviparin sodiumTreatment of deep vein thrombosis which may lead to pulmonary embolism in pediatric patients | Abbott | Designated |
| Jan 2, 1986 | Antithrombin III humanPreventing or arresting episodes of thrombosis in patients with congenital AT-III deficiency and/or to prevent the occurrence of thrombosis… | American National Red Cross | Designated |
| Nov 21, 2025 | Svariya (previously Rivaroxaban Koanaa)Rivaroxaban · generic | PGF Pharma International d.o.o. | EMA ↗ |
| Nov 16, 2020 | Rivaroxaban AccordRivaroxaban · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Mar 20, 2002 | ArixtraFondaparinux sodium | Viatris Healthcare Limited | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA